Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 15, 2002 03:52 ET | Source: Active Biotech

Active Biotech Interim Report April-June 2002

The full Interim Report including tables is available to download from the enclosed link....
August 15, 2002 03:24 ET | Source: Active Biotech

Active Biotech Kvartalsrapport April-juni 2002

Hela rapporten inklusive tabeller finns att ladda ner från medföljande länk....
August 12, 2002 05:16 ET | Source: Active Biotech

Teleconference - Active Biotech AB

To listen to the teleconference live, please call +44 20 8240 8243. To view the presentation: please visit www.activebiotech.com. To listen to the conference and to view the...
August 12, 2002 05:12 ET | Source: Active Biotech

Telekonferens - Active Biotech AB

För att lyssna på telefonkonferensen, v.v. ring +44 20 8240 8243 För att samtidigt följa presentationen: besök www.activebiotech.com. Vill ni gå in och lyssna och se på...
June 24, 2002 05:38 ET | Source: Active Biotech

Active Biotech has selected a new Candidate Drug for the treatment of SLE

Active Biotech has selected a Candidate Drug, ABR-215757, within the SLE project for further development into clinical phase. The SLE project is included in the company's "competence...
June 24, 2002 05:22 ET | Source: Active Biotech

Active Biotech har valt läkemedelskandidat för SLE-projektet

SLE-projektet ingår i företagets s.k. "Q-kompetensplattform". Ytterligare projekt baserade på denna kompetens är SAIK-MS, som befinner sig i klinisk utveckling Fas II för behandling av multipel...
May 31, 2002 08:11 ET | Source: Active Biotech

Active Biotech’s drug for the treatment of Multiple Sclerosis

Active Biotech’s drug for the treatment of MS, SAIK-MS, is currently in clinical Phase II, where the efficacy is verified on MS patients. The ongoing study is a multi-center study where 180...
May 31, 2002 08:09 ET | Source: Active Biotech

Active Biotechs läkemedel mot multipel skleros

Active Biotechs läkemedel mot MS, SAIK-MS, befinner sig i klinisk Fas II, varvid preparatets effekt verifieras på MS-patienter. Den pågående prövningen är en multicenterstudie, vari 180 patienter...
May 16, 2002 08:25 ET | Source: Active Biotech

Active Biotech AB, Interim Report January-March 2002

* Treatment of MS patients in Sweden started as part of the SAIK-MS Phase II clinical study * TTS Phase II cancer studies proceeding as planned - renal cancer patients now receiving treatment,...
May 16, 2002 03:00 ET | Source: Active Biotech

Active Biotech AB, Kvartalsrapport januari-mars 2002

* Behandling av MS-patienter i Sverige inledd för SAIK-MS Fas II klinisk studie * TTS Fas II-cancerstudier fortskrider som planerat - njurcancerpatienter under behandling, inkludering av...